Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 300,260 shares of the company's stock, valued at approximately $5,531,000. Carnegie Investment Counsel owned 0.14% of Hims & Hers Health at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC raised its position in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC lifted its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after acquiring an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth $111,000. Finally, Amalgamated Bank grew its stake in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on HIMS shares. Bank of America raised their price objective on shares of Hims & Hers Health from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Monday. Truist Financial lifted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a "hold" rating in a research report on Thursday, July 18th. Piper Sandler restated a "neutral" rating and issued a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th. TD Cowen lifted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, July 11th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a "hold" rating in a report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $20.07.
Get Our Latest Research Report on Hims & Hers Health
Hims & Hers Health Stock Performance
Hims & Hers Health stock traded up $1.80 during midday trading on Monday, reaching $20.49. The stock had a trading volume of 19,087,981 shares, compared to its average volume of 8,171,444. The stock has a market capitalization of $4.40 billion, a PE ratio of -1,994.00 and a beta of 1.06. The stock's 50-day simple moving average is $16.41 and its 200 day simple moving average is $17.38. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million during the quarter, compared to analysts' expectations of $302.43 million. During the same quarter in the previous year, the business earned ($0.03) EPS. The company's revenue for the quarter was up 51.8% on a year-over-year basis. Equities analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company's stock, valued at approximately $487,789.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company's stock, valued at $487,789.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $19.96, for a total value of $196,965.28. Following the sale, the chief financial officer now directly owns 195,988 shares in the company, valued at approximately $3,911,920.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 564,305 shares of company stock valued at $9,124,922. Company insiders own 17.71% of the company's stock.
Hims & Hers Health Profile
(
Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Stories
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.